Special Investigation in Patients With Ulcerative Colitis

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by AbbVie
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: September 18, 2013
Last updated: May 13, 2016
Last verified: May 2016

This investigation will be conducted to obtain the following information regarding the use of Humira 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Ulcerative Colitis.

  1. Unknown adverse reactions (in particular, clinically significant)
  2. Incidence and conditions of occurrence of adverse reactions in clinical practice
  3. Factors likely to affect the safety and effectiveness

Ulcerative Colitis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Special Investigation in Patients With Ulcerative Colitis

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Number of patients with adverse events [ Time Frame: Up to Week 52 ] [ Designated as safety issue: Yes ]
    Number of patients with adverse events with evaluation beginning upon administration of Humira

Secondary Outcome Measures:
  • Full Mayo score [ Time Frame: Up to week 52 ] [ Designated as safety issue: No ]
  • Partial Mayo score [ Time Frame: Up to week 52 ] [ Designated as safety issue: No ]
  • C-reactive Protein [ Time Frame: Up to week 52 ] [ Designated as safety issue: No ]
  • Mayo endoscopic sub-score [ Time Frame: Up to week 52 ] [ Designated as safety issue: No ]

Estimated Enrollment: 1500
Study Start Date: August 2013
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Humira 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration


Ages Eligible for Study:   up to 99 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients for the first time receiving Humira for the treatment of Ulcerative Colitis

Inclusion Criteria:

- Patients receiving Humira for the first time for the treatment of Ulcerative Colitis

Exclusion Criteria:

Contraindications according to the Package Insert include patients who have any of the following:

  • serious infections
  • tuberculosis
  • a history of hypersensitivity to any ingredient of Humira
  • demyelinating disease or a history of demyelinating disease
  • congestive cardiac failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01947816

Contact: Abbvie Japan PMOS Desk +81-3-4577-1125 AbbVie_JPN_info_clingov@abbvie.com
Contact: Yasuhiko Shinmura

  Show 526 Study Locations
Sponsors and Collaborators
Study Director: Osamu Mikami, MD AbbVie GK
  More Information

Additional Information:
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT01947816     History of Changes
Other Study ID Numbers: P14-190 
Study First Received: September 18, 2013
Last Updated: May 13, 2016
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by AbbVie:
Ulcerative Colitis

Additional relevant MeSH terms:
Colitis, Ulcerative
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 26, 2016